ZIOPHARM Oncology is a biopharmaceutical company engaged in developing and commercializing new cancer therapies. The company’s clinical programs include palifosfamide, currently being studied in two Phase 3 clinical trials; Ad-RTS IL-12, currently being tested in a Phase 2 clinical study; indibulin (ZIO-301), currently being studied in a Phase 1/2 trial; and darinaparsin (ZIO-101), currently part of ongoing studies with Solasia Pharma K.K. ZIOPHARM has operations in both Boston, Mass., and New York City. For more information, visit the company’s Web site at www.zionpharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: